Uni-Bio Science Group (0690) Fundamentals 2026 — P/E 5.4x, Revenue Analysis | SniperIQ
Uni-Bio Science Group (0690) is a HK-listed Healthcare company in Biotechnology with a market capitalization of HK$502M, trading at HK$0.08 on the HKSE. This SniperIQ fundamentals page covers Uni-Bio Science Group's valuation (P/E 5.4x, P/B 1.2x), profitability (net margin 15.9%), revenue (HK$586M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Uni-Bio Science Group's market cap?
Uni-Bio Science Group (0690) has a market capitalization of approximately HK$502M, trading at HK$0.08 on the HKSE. Market cap moves with the live share price.
What is Uni-Bio Science Group's P/E ratio?
Uni-Bio Science Group's trailing twelve-month P/E ratio is 5.4x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Uni-Bio Science Group?
Uni-Bio Science Group runs a net profit margin of 15.9%, a gross margin of 83.2%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Uni-Bio Science Group generate?
Uni-Bio Science Group reported revenue of HK$586M for fiscal year 2025, with net income of HK$93M and earnings per share (EPS) of 0.0156. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Uni-Bio Science Group pay a dividend?
Uni-Bio Science Group offers a trailing dividend yield of about 3.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Uni-Bio Science Group financially healthy?
Uni-Bio Science Group carries a debt-to-equity ratio of 0.24x and a current ratio of 3.23x, with a market beta of -0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Uni-Bio Science Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Uni-Bio Science Group (0690) the key facts are: market cap HK$502M, P/E 5.4x, revenue HK$586M, 52-week range 0.076-0.168. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Uni-Bio Science Group's full fundamentals live
Get Uni-Bio Science Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.